SCHEMBL6325983

SCHEMBL6325983

C[C@@H](C(=O)NCC1CCCO1)C(N)c1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 6/20 0.64
CYP3A4 P08684 1/20 0.61
CYP2D6 P10635 1/20 0.61
CYP2C9 P11712 1/20 0.61
PKM P14618 1/20 0.61
CYP2C19 P33261 1/20 0.61
CYP1A2 P05177 1/20 0.56
ALDH1A1 P00352 5/20 0.53
LMNA P02545 1/20 0.53
POLB P06746 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
GPR88 Q9GZN0 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.51
GLA P06280 1/20 0.50
ALOX12 P18054 1/20 0.50
KDM4E B2RXH2 1/20 0.50
HSD17B10 Q99714 1/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16308879 0.76 SMN1; SMN2 (0.59) HPGDCYP3A4CYP2D6CYP2C9PKM
SCHEMBL12312072 0.75 MEN1 (0.54) HPGDCYP1A2LMNAPOLBSMN1; SMN2
SCHEMBL12573346 0.75 MEN1 (0.54) HPGDCYP1A2LMNAPOLBSMN1; SMN2
Hydrochloric Acid SCHEMBL16286916 0.75 SMN1; SMN2 (0.58) HPGDCYP3A4CYP2D6CYP2C9PKM
SCHEMBL8404634 0.74 MEN1 (0.59) HPGDCYP1A2LMNAPOLBSMN1; SMN2
SCHEMBL14368076 0.74 MEN1 (0.59) HPGDCYP1A2LMNAPOLBSMN1; SMN2
SCHEMBL12880452 0.74 MEN1 (0.59) HPGDCYP1A2LMNAPOLBSMN1; SMN2
SCHEMBL16310100 0.74 SMN1; SMN2 (0.60) HPGDCYP3A4CYP2D6CYP2C9PKM
SCHEMBL6316867 0.74 CYP1A2 (0.59) HPGDCYP3A4CYP2D6CYP2C9PKM
SCHEMBL6512150 0.73 MEN1 (0.52) HPGDCYP1A2ALDH1A1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6939880-B2 Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 2005-09-06 US disclosed
US-6555570-B2 Growth hormone secretagogous with improved bioavailability NOVO NORDISK A/S (DE) 2003-04-29 US disclosed
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 US disclosed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 US disclosed
US-6127391-A A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 2000-10-03 US disclosed
US-5977178-A Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 1999-11-02 US disclosed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 EP disclosed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055261-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, IGFBP1 HPGD 2445/4885CYP3A4 3623/4885CYP2D6 1979/4885
US-20030040483-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, GRPR HPGD 2185/4885CYP3A4 3566/4885CYP2D6 2164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.